Biotech Startups

Ametris provides sensor-based digital measures and digital endpoints for clinical trials, capturing data from wearable sensors and real-world patient insights. Now part of Signant Health, it supports clinical trial sponsors running decentralized, hybrid, and traditional studies alongside electronic Clinical Outcome Assessment (eCOA) capabilities.

1 investor

1 investor

The Amgen Foundation funds and runs science education programs, providing teachers with research equipment and training and offering hands-on and virtual learning opportunities to students and scholars. It partners with nonprofits and universities and awards grants in U.S. and Puerto Rican communities to broaden access to science education.

1 investor

Amino Analytica designs rapid molecular diagnostic tests for emerging infectious diseases and biological threats, developed in weeks rather than the traditional 12+ months. The company combines point-of-care diagnostics technology with AI-driven bionanotechnology to enable earlier detection and faster pandemic response.

1 investor

Amizona Scientific sells laboratory equipment and consumables, including centrifuges, homogenizers, rockers, rotators, pipettors, and filtration sets, for research and lab use.

1 investor

AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma. The company translates cancer biomarker research into tests designed to stratify patient risk and optimize treatment allocation.

1 investor

AMMEVA produces human-milk fortifiers and breast-milk powder made exclusively from donated breast milk, using a patented freeze-drying and microfiltration process. The products supply hospital neonatal units treating premature and sick infants across Germany.

1 investor

Amoy Diagnostics develops molecular diagnostic test kits for cancer detection, including PCR, IHC, FISH, and next-generation sequencing products that detect gene mutations such as PIK3CA, KRAS, NRAS, BRAF, and IDH1, as well as microsatellite instability. Its products serve clinical and oncology diagnostics and include related nucleic acid extraction reagents and instruments.

1 investor

Ampersand develops a drug-design platform that localizes therapeutics to specific disease sites by separating molecular specificity from biological effect, producing "AND-Body" medicines across formats such as proteins, small molecules, LNPs, and nucleic acids. The company applies computational modeling, multi-omics mapping, and high-throughput binder generation to identify and engineer targets for next-generation therapeutics.

1 investor

Amphastar Pharmaceuticals manufactures and distributes generic and branded pharmaceutical products, including injectable medications, inhalation aerosols, and emergency treatments for medical professionals and patients in the United States.

1 investor

1 investor

Amplicore Pharma develops an injectable pharmaceutical formulation targeting musculoskeletal disorders, particularly osteoarthritis, designed to slow cartilage degeneration and reduce symptoms as an alternative to joint replacement surgery.

1 investor

Amplifi Vascular develops the Amplifi Vein Dilation System, a wearable external blood pump with inflow and outflow catheters that uses proprietary hemodynamic technology to enlarge veins before arteriovenous fistula (AVF) creation. The device is intended to increase patient eligibility for AVF surgery and improve vascular access outcomes for hemodialysis patients.

1 investor

Amplifier Therapeutics is a biotech company developing an AMPK activator drug intended to restore cellular metabolism and treat or prevent chronic, aging-related diseases. It is presented as a subsidiary ("PipeCo") of Cambrian Bio.

1 investor

Amplify Dynamics develops an ultrasound-based, contactless purification system for lipid nanoparticles (LNPs) used in therapeutics, aimed at increasing particle recovery, throughput, and sustainability compared to membrane-based methods. It serves therapeutic discovery and pharmaceutical production workflows.

1 investor

Amplifyer develops liquid biopsy technology aimed at improving outcomes for cancer patients. The company operates in the biotech and diagnostics space.

1 investor

Amplitude Therapeutics is a biotechnology company developing RNA-based medicines. The company is operating in stealth mode.

1 investor

Amplitude VC creates, builds, and grows companies specializing in precision medicine to transform patient outcomes. The firm invests from ideation through patient care, focusing on innovations in human health.

1 investor

Amplo Biotechnology develops adeno-associated virus (AAV) gene therapies for genetic diseases of the neuromuscular junction, targeting rare and ultra-rare patient populations such as those with Congenital Myasthenic Syndromes. Its work focuses on delivering proteins like Dok-7 and Collagen Q that are essential to neuromuscular junction function.

1 investor

Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.

1 investor

Amprion offers SAAmplify-αSYN, a clinically validated diagnostic test that detects misfolded (pathological) α-synuclein in cerebrospinal fluid to aid diagnosis of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and Alzheimer's. The seed amplification assay is aimed at physicians and researchers, providing biology-based evidence to support diagnosis of mixed neurodegenerative pathologies.

1 investor

Amprion develops and offers SAAmplify-αSYN, a validated diagnostic test that detects misfolded pathological α-synuclein in cerebrospinal fluid to support the diagnosis of neurodegenerative disorders such as Parkinson's, Lewy body dementia, and Alzheimer's. It serves physicians and researchers seeking biological confirmation of neurodegenerative disease.

1 investor

AMR Bio develops XF-73, a first-in-class topical antimicrobial candidate in Phase 3 trials designed to prevent post-surgical infections, with the lead program targeting pre-operative decolonization in surgical settings. The company also advances dermal formulations for severe wound and skin infections.

1 investor

Curia is a CDMO (Contract Development and Manufacturing Organization) providing drug discovery, development, and manufacturing services across small molecules, generic APIs, sterile drug products, and biologics for biopharma companies.

1 investor